The farnesoid X receptor (FXR) is a nuclear receptor superfamily member and ligand-activated transcription factor. By binding to DNA as a monomer or a heterodimer with the common NR partner, retinoid x receptor (RXR), to FXR response elements, FXR controls the expression of numerous genes. The FXR and FXR genes are the two recognized FXR genes.
FXR is primarily expressed in the liver and small intestine, where it is critical for the metabolism of bile acids, lipids, and glucose. FXR regulates bile acid (BA) synthesis and homeostasis, glucose and lipid metabolism, as well as playing a significant role in intestinal bacterial growth and liver regeneration through its specific target genes.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V85288 | (E)-GW 4064 | 1089660-72-9 | |
|
V1844 | Obeticholic Acid (6-ECDCA; INT-747) | 459789-99-2 | Obeticholic Acid (INT747; 6-ECDCA; 6-Ethylchenodeoxycholic acid; trade name Ocaliva), a novel derivative of cholic acid, is a potent,orally bioactive and selectiveagonist of farnesoid X receptor (FXR) with EC50 of 99 nM, and has anticholeretic and anti-inflammatory activities. |
|
V74026 | Alismanol M | 2408810-59-1 | Alismanol M is an agonist of farnesoid X receptor (FXR) with EC50 of 50.25 μM. |
|
V94855 | BAR-2227 | 2409154-23-8 | BAR-2227 (compound 3a) is a FXR agonist and LIFR inhibitor. |
|
V18332 | Cilofexor | 1418274-28-8 | Cilofexor, formerly known as GS-9674, is a farnesoid X receptor (FXR) agonist. |
|
V94323 | Cilofexor tromethamine | 2253764-93-9 | Cilofexor tromethamine (GS-9674 tromethamine) is a nonsteroidal oxidized farnesene receptor agonist with activity in improving markers of cholestasis and liver injury. |
|
V74025 | Fargesone A | 116424-69-2 | Fargesone A is a potent and specific FXR agonist. |
|
V87447 | FXR agonist 3 | FXR agonist 3 is an anti-NASH agent that acts by activating FXR. | |
|
V87448 | FXR agonist 4 | 3025841-47-5 | FXR agonist 4 (compound 10a) is a farnesoid X receptor (FXR) agonist with an EC50 value of 1.05 μM. |
|
V87449 | FXR agonist 7 | FXR agonist 7 (compound 33) is a potent agonist of FXR with an EC50 of 0.1 nM. | |
|
V74032 | FXR antagonist 1 | 2295804-68-9 | FXR antagonist 1 (Compound F6) is an orally bioactive, selective intestinal FXR antagonist (IC50=2.1 μM). |
|
V74028 | FXR antagonist 2 | 1660153-21-8 | FXR antagonist 2 (compound A-26) is a diarylamide analogue, as well as a moderate FXR antagonist. |
|
V85497 | FXR antagonist 3 | 3024652-96-5 | |
|
V94530 | FXR/CES2 modulator 1 | 3004676-87-0 | FXR/CES2 modulator 1 (compound LE-77) is a dual modulator that activates FXR and inhibits CES2. |
|
V78496 | FXRagonist 3 | FXR agonist 3 is an anti-NASH agent that acts by activating FXR. | |
|
V79540 | FXRagonist 4 | FXR agonist 4 (compound 10a) is a farnesoid X receptor (FXR) agonist/activator with EC50 of 1.05 μM. | |
|
V74031 | FXRagonist 5 | 2414008-05-0 | FXR agonist 5 (compound 1) is an FXR agonist. |
|
V29731 | Gly-β-MCA | 66225-78-3 | Gly-β-MCA is a bile acid acting as an oral and potent farnesoid X receptor (FXR) inhibitor with the potential to be usedfor the treatment of metabolic disorders. |
|
V79622 | Glyco-obeticholic acid-d5 (obeticholic acid impurity 8-d5) | Glyco-Obeticholic acid-d5 is the deuterated form of Glyco-Obeticholic acid. | |
|
V74024 | HEC96719 | 2181834-03-5 | HEC96719 is a selective and orally bioactive tricyclic farnesoid X receptor (FXR) agonist/activator with EC50s of 1.37 and 1.55 nM via time-resolved fluorescence energy transfer (TR-FRET) and luciferase, respectively. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
